Format

Send to

Choose Destination
Oncotarget. 2016 Mar 1;7(9):10051-63. doi: 10.18632/oncotarget.7067.

Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival.

Author information

1
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Abstract

As tumors accumulate genetic alterations, an evolutionary process occurs in which genetically distinct subclonal populations of cells co-exist, resulting in intratumor genetic heterogeneity (ITH). The clinical implications of ITH remain poorly defined. Data are limited with respect to whether ITH is an independent determinant of patient survival outcomes, across different cancer types. Here, we report the results of a pan-cancer analysis of over 3300 tumors, showing a varied landscape of ITH across 9 cancer types. While some gene mutations are subclonal, the majority of driver gene mutations are clonal events, present in nearly all cancer cells. Strikingly, high levels of ITH are associated with poorer survival across diverse types of cancer. The adverse impact of high ITH is independent of other clinical, pathologic and molecular factors. High ITH tends to be associated with lower levels of tumor-infiltrating immune cells, but this association is not able to explain the observed survival differences. Together, these data show that ITH is a prognostic marker in multiple cancers. These results illuminate the natural history of cancer evolution, indicating that tumor heterogeneity represents a significant obstacle to cancer control.

KEYWORDS:

cancer; evolution; heterogeneity; immune surveillance; survival

PMID:
26840267
PMCID:
PMC4891103
DOI:
10.18632/oncotarget.7067
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center